These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3165439)

  • 41. Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients.
    Vaamonde J; Luquin MR; Obeso JA
    Brain; 1991 Feb; 114 ( Pt 1B)():601-17. PubMed ID: 2004258
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lisuride in the treatment of Parkinsonism.
    Schachter M; Sheehy MP; Parkes JD; Marsden CD
    Acta Neurol Scand; 1980 Dec; 62(6):382-5. PubMed ID: 7468157
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lisuride in Parkinson's disease.
    Schachter M; Blackstock J; Dick JP; George RJ; Marsden CD; Parkes JD
    Lancet; 1979 Nov; 2(8152):1129. PubMed ID: 91855
    [No Abstract]   [Full Text] [Related]  

  • 44. Pharmacokinetics and endocrine effects of terguride in healthy subjects.
    Krause W; Träger H; Kühne G; Sauerbrey N; Gräf KJ; Dorow R
    Eur J Clin Pharmacol; 1990; 38(6):609-15. PubMed ID: 2373136
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Unusual cardiovascular response to intravenous lisuride bolus. Possible drug-induced coronary angiospasm.
    Capria A; Stocchi F; Attanasio A; Quatrana M; Cannata D; Ruggieri S
    Chest; 1987 May; 91(5):792-3. PubMed ID: 3568790
    [No Abstract]   [Full Text] [Related]  

  • 46. [Lactation inhibition with various dosages of lisuride--prolactin secretion and effectiveness].
    Strahl HJ; Göretzlehner G; Strahl S; Kunkel S
    Zentralbl Gynakol; 1985; 107(5):300-3. PubMed ID: 4039514
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease.
    Rinne UK
    Neurology; 1989 Mar; 39(3):336-9. PubMed ID: 2927639
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Lisuride in Parkinson disease].
    Leiguarda R; Micheli F; Fernández Pardal M
    Medicina (B Aires); 1985; 45(1):29-34. PubMed ID: 3880105
    [No Abstract]   [Full Text] [Related]  

  • 49. Bromocriptine and lisuride in Parkinson disease.
    Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Walker R; Hiesiger E
    Ann Neurol; 1983 Jan; 13(1):44-7. PubMed ID: 6830164
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lisuride in parkinsonism.
    Gopinathan G; Teräväinen H; Dambrosia JM; Ward CD; Sanes JN; Stuart WK; Evarts EV; Calne DB
    Neurology; 1981 Apr; 31(4):371-6. PubMed ID: 7194429
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease.
    Stocchi F; Ruggieri S; Vacca L; Olanow CW
    Brain; 2002 Sep; 125(Pt 9):2058-66. PubMed ID: 12183351
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The pharmacokinetics and biotransformation of 14C-lisuride hydrogen maleate in rhesus monkey and in man.
    Hümpel M; Krause W; Hoyer GA; Wendt H; Pommerenke G
    Eur J Drug Metab Pharmacokinet; 1984; 9(4):347-57. PubMed ID: 6532807
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lisuride in the treatment of parkinsonism.
    McDonald RJ; Horowski R
    Eur Neurol; 1983; 22(4):240-55. PubMed ID: 6884394
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The pharmacokinetics of lisuride hydrogen maleate in rat, rabbit and rhesus monkey.
    Humpel M; Toda T; Oshino N; Pommerenke G
    Eur J Drug Metab Pharmacokinet; 1981; 6(3):207-19. PubMed ID: 7308240
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Oral lisuride in Parkinson's disease].
    Obeso JA; Luquin MR; Martínez Lage JM
    Med Clin (Barc); 1985 Sep; 85(8):307-12. PubMed ID: 4068822
    [No Abstract]   [Full Text] [Related]  

  • 56. [Is dopaminergic therapy immunologically rejuvinating? Increased interferon-gamma production with the dopaminergic agent lisuride].
    Poehlau D; Baier JE; Kovacs S; Gallati H; Suchy I; Will C; Schmutz T; Neumann HA; Przuntek H
    Fortschr Med; 1994 Apr; 112(12):174-6. PubMed ID: 8200605
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Psychiatric side-effects of high-dose lisuride therapy in parkinsonism.
    Horowski R
    Lancet; 1986 Aug; 2(8505):510. PubMed ID: 2875253
    [No Abstract]   [Full Text] [Related]  

  • 58. Pharmacokinetics and pharmacodynamics of the ergot derivative, transdihydrolisuride, in man.
    Krause W; Dorow R; Nieuweboer B; Hasan SH
    Eur J Clin Pharmacol; 1984; 27(3):335-9. PubMed ID: 6510462
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease].
    Nomoto M; Iwata S; Irifune M; Kaseda S; Osame M; Fukuda T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):81-7. PubMed ID: 9800199
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Continuous dopaminergic stimulation in the management of complicated Parkinson's disease.
    Agnoli A; Stocchi F; Carta A; Antonini A; Bragoni M; Ruggieri SA
    Mt Sinai J Med; 1988 Jan; 55(1):62-6. PubMed ID: 3258057
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.